Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03489629 · ClinicalTrials.gov registry record · Phase 2
STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT03489629: Completed Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
NCT03489629 is a Phase 2 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 37 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03489629, a Phase 2 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
To evaluate the micro-biologic efficacy and safety of a streamlined treatment for early onset methicillin-resistant staphylococcus aureus (MRSA) in patients with cystic fibrosis.
Primary Outcome
Descriptive summary with corresponding 95% confidence interval.
Interventions
- DRUG Chlorhexidine Gluconate
- DRUG Minocycline
- DRUG Mupirocin
- DRUG Trimethoprim Sulfamethoxazole (TMP/SMX)
- BEHAVIORAL Environmental Decontamination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2018-04-03 |
| Est. Completion | 2026-01-31 |
| Phase | Phase 2 |
What the finished NCT03489629 record still lists
NCT03489629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 5 interventions - of which Chlorhexidine Gluconate is the first listed.
NCT03489629 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03489629 about?
NCT03489629 is a clinical study titled "STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)". To evaluate the micro-biologic efficacy and safety of a streamlined treatment for early onset methicillin-resistant staphylococcus aureus (MRSA) in patients with cystic fibrosis.
What is the current status of trial NCT03489629?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2018-04-03. Estimated completion is 2026-01-31.
What interventions are being tested in trial NCT03489629?
The interventions under investigation include: Chlorhexidine Gluconate (DRUG), Minocycline (DRUG), Mupirocin (DRUG), Trimethoprim Sulfamethoxazole (TMP/SMX) (DRUG), Environmental Decontamination (BEHAVIORAL).
Who is sponsoring clinical trial NCT03489629?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03489629's enrollment target sits among peer trials
37 1484th of 2000 higher than 505 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI